NALP7 Antibody
| Code | Size | Price |
|---|
| PSI-5963-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5963-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
NALP7 Antibody: HYDM, PAN7, NALP7, NOD12, PYPAF3, CLR19.4, NACHT, LRR and PYD domains-containing protein 7, Nucleotide-binding oligomerization domain protein 12
Application Note:
NALP7 antibody can be used for detection of NALP7 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
NALP7 Antibody: NOD proteins include the apoptosis regulator APAF1 (apoptotic protease activating factor 1) and mammalian NOD-LRR proteins. NALP7, also known as PYPAF3, a member of the related PYRIN-containing APAF1-like proteins (PYPAFs/NALPs) is thought to play a crucial role in cell proliferation. NALP7 has a C-terminal leucine-rich repeat (LRR) region, an N-terminal Pyrin domain (PYD) followed by a NACHT domain, and a NACHT-associated domain. It is expressed in numerous tissues including uterus and ovary, with low levels in heart and brain. NALP7 inhibits caspase-1-dependent interleukin-1β secretion and is a feedback regulator of interleukin-1β secretion. Defects in the NALP7 gene are known to cause the formation of a hydatidiform mole (HYDM) and reduce the growth of carcinoma cell lines.
Background References:
- Tschopp J, Martinon F, and Burns K. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol.2003; 4:95-104.
- Kinoshita T, Wang Y, Hasegawa M, et al. PYPAF3, a PYRIN-containing APAF-1-like protein, is a feedback regulator of caspase-1-dependent interleukin-1beta secretion. J. Biol. Chem.2005; 280:21720-5.
- Okada K, Hirota E, Mizutani Y, et al. Oncogenic role of NALP7 in testicular seminomas. Cancer Sci.2004; 95: 949-54.
- Murdoch S, Djuric U, Mazhar B, et al. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat. Genet.2006; 38: 300-2.
Buffer:
NALP7 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
NALP7 antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of human NALP7.
The immunogen is located within amino acids 90 - 140 of NALP7.
The immunogen is located within amino acids 90 - 140 of NALP7.
NCBI Gene ID #:
199713
NCBI Official Name:
NLR family, pyrin domain containing 7
NCBI Official Symbol:
NLRP7
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_631915
Protein GI Number:
46049100
Purification:
NALP7 Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
Swissprot #:
Q8WX94
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | NALP7 Peptide | PSI-5963P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|